SCHEDULE: BlackRock Discloses 5.5% Stake in GeneDx Holdings Corp.
Beneficial Ownership Filing
BlackRock, Inc. has reported a beneficial ownership of 5.5% in GeneDx Holdings Corp. Class A Stock, as of June 30, 2026.
Summary
- BlackRock, Inc. has filed a Schedule 13G, indicating its beneficial ownership of GeneDx Holdings Corp. Class A Stock.
- The filing, dated June 30, 2026, shows BlackRock beneficially owns 1,622,518 shares.
- This represents 5.5% of the total outstanding Class A Stock.
- BlackRock has sole voting power over 1,588,670 shares and sole dispositive power over 1,622,518 shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership by an institutional investor and does not contain operational or financial performance updates.
Positives
- BlackRock, a significant institutional investor, has taken a notable stake in GeneDx Holdings Corp.
- The 5.5% ownership indicates confidence from a major financial institution.
Future Outlook
No specific forward-looking statements or guidance were provided in this Schedule 13G filing.
Industry Context
StockSavvy.ai notes that the acquisition of a significant stake by a major asset manager like BlackRock in a company like GeneDx Holdings Corp. often signals potential growth or strategic importance within the biotechnology or diagnostics sector.
Stakeholder Impact
- Shareholders: The increased institutional ownership by BlackRock may lead to greater market liquidity and potentially influence the company's strategic direction.
- Management: The presence of a significant institutional investor like BlackRock can bring increased scrutiny and expectations regarding performance and governance.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney dated April 30, 2023, revoked by the new power of attorney. |
| 2025-01-21 | Date of execution of the new Power of Attorney by BlackRock, Inc. |
| 2026-06-30 | Date of event requiring the filing of the Schedule 13G. |
| 2026-07-28 | Date of signature by Spencer Fleming, Managing Director for BlackRock, Inc. |
Keywords
GeneDx Holdings Corp., BlackRock, Inc., Schedule 13G, Class A Stock, Beneficial Ownership, Institutional Investor, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.